Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy Of Eculizumab In Patients With Relapsing Neuromyelitis Optica (NMO)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Neuromyelitis optica
- Focus Registrational; Therapeutic Use
- Acronyms PREVENT
- Sponsors Alexion AstraZeneca Rare Disease
- 08 Apr 2024 According to an Alexion Pharmaceuticals media release, company will present oral presentation highlighting results from this trial at the American Academy of Neurology (AAN) Annual Meeting in Denver, CO, 13 to 18 April 2024
- 18 Oct 2023 According to an AstraZeneca media release, Soliris (eculizumab) has been approved by the National Medical Products Administration (NMPA) in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD).
- 13 Oct 2023 Results of post-hoc analysis assessing safety outcomes in patients who initiated C5IT treatment within 1 year of last rituximab exposure in the PREVENT and CHAMPION-NMOSD studies, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.